September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Car­du­ri­on Phar­ma­ceu­ti­cals: A shot at one of heart dis­ease’s 'un­drug­gable' tar­gets

Lei Lei Wu

News Reporter

↑
  • CEO Pe­ter Lawrence
  • To­tal raised More than $500 mil­lion
  • Head­quar­ters Burling­ton, MA

‘Un­drug­gable’ tar­gets aren’t just in on­col­o­gy. Car­du­ri­on Phar­ma­ceu­ti­cals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

Up­dat­ed: FDA ad­comm votes to lim­it Op­di­vo, Keytru­da use in stom­ach, esophageal can­cers based on key bio­mark­er

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

ARCH, biotech's star slug­ger, snags an­oth­er $3B for 13th fund

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times